Rivastigmine for Dementia Associated with Parkinson's Disease
New England Journal of MedicinePublished 9 December 2004Open access
Murat Emre, Dag Aarsland, Alberto Albanese, E. Jane Byrne, Günther Deuschl, Peter Paul De Deyn
Citations1,193
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Rivastigmine was associated with moderate improvements in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor; however, the differences between these two groups were moderate and similar to those reported in trials of rivastIGmine for Alzheimer's disease.
Abstract
In this placebo-controlled study, rivastigmine was associated with moderate improvements in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor.
Keywords
Medicine
Encyclopedia of Social WorkDiagnostic and Statistical Manual of Mental Disorders
109,983 Citations2013Janet B. W. Williams, Michael B. First
Journal of Psychiatric Research“Mini-mental state”
86,858 Citations1975Marshal F. Folstein, Susan E. Folstein +1 more
A simplified, scored form of the cognitive mental status examination, the “Mini-Mental State” (MMS) which includes eleven questions, requires only 5-10 min to administer, and is therefore practical to use serially and routinely.
Neurobiology of AgingStaging of brain pathology related to sporadic Parkinson’s disease
10,754 Citations2002Heiko Braak, Kelly Del Tredici +4 more
This study traces the course of the pathology in incidental and symptomatic Parkinson cases proposing a staging procedure based upon the readily recognizable topographical extent of the lesions.
NeurologyThe Neuropsychiatric Inventory
7,559 Citations1994Jeffrey L. Cummings, Michael S. Mega +4 more
The NPI has the advantages of evaluating a wider range of psychopathology than existing instruments, soliciting information that may distinguish among different etiologies of dementia, differentiating between severity and frequency of behavioral changes, and minimizing administration time.
American Journal of PsychiatryA new rating scale for Alzheimer's disease
4,123 Citations1984Wilma G. Rosen, Richard C. Mohs +1 more
A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease.
Journal of Neurology Neurosurgery & PsychiatryThe relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
3,447 Citations1988W R Gibb, Andrew J. Lees
NeurologyPractice parameter: Management of dementia (an evidence-based review) [RETIRED]
1,722 Citations2001Rachelle S. Doody, J E Stevens +9 more
New England Journal of MedicineAromatic Amino Acids and Modification of Parkinsonism
1,483 Citations1967George C. Cotzias, Melvin H. Van Woert +1 more
The interrelations between melanogenesis and extrapyramidal disease might be of fundamental importance and it was noted that chronic Parkinson's disease has a common precursor in the synthesis of both melanin and catecholamines.
Archives of NeurologyPrevalence and Characteristics of Dementia in Parkinson Disease
1,383 Citations2003Dag Aarsland, Kjeld Andersen +2 more
Early hallucinations and akinetic-dominant PD were associated with an increased risk of dementia, and more than three quarters of this representative PD cohort developed dementia during the 8-year study period.
Journal of Neurology Neurosurgery & PsychiatryWhat contributes to quality of life in patients with Parkinson's disease?
1,375 Citations2000Anette Schrag
Depression, disability, postural instability, and cognitive impairment have the greatest influence on QoL in Parkinson's disease, and the improvement of these features should become an important target in the treatment of the disease.
The LancetEfficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
1,183 Citations2000Ian G. McKeith, Teodoro del Ser +7 more
Rivastigmine 6-12 mg daily produces statistically and clinically significant behavioural effects in patients with Lewy-body dementia, and seems safe and well tolerated if titrated individually.
Alzheimer Disease & Associated DisordersAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
1,163 Citations1997Douglas Galasko, David A. Bennett +5 more
Movement DisordersSydney multicenter study of Parkinson's disease: Non‐<scp>L</scp>‐dopa–responsive problems dominate at 15 years
1,043 Citations2004M. A. Hely, John G. Morris +2 more
It is concluded that the most disabling long‐term problems of Parkinson's disease relate to the emergence of symptoms that are not improved by L‐dopa, and neuroprotective interventions in Parkinson’s disease should be judged by their ability to improve non‐L‐Dopa–responsive aspects of the disease.
PubMedAn inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
774 Citations1997Doug Galasko, David Bennett +5 more
Alzheimer Disease & Associated DisordersValidity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of Change
652 Citations1997Lara Schneider, Jason T. Olin +8 more
The ADCS-CGIC ratings at 12 months were significantly associated with change on four severity scales, and change ratings were sensitive to dementia severity.
The Lancet NeurologyDementia with Lewy bodies
608 Citations2003Ian G. McKeith, Jacobo Mintzer +16 more
Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms and clear guidance on the management of DLB is urgently needed.
Journal of Neurology Neurosurgery & PsychiatryCholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.
575 Citations1985E K Perry, Maria Curtis +8 more
In Parkinson's but not Alzheimer's disease the decrease in neocortical (particularly temporal) choline acetyltransferase correlated with the number of neurons in the nucleus of Meynert suggesting that primary degeneration of these cholinergic neurons may be related, directly or indirectly, to declining cognitive function in Parkinson's disease.
Archives of NeurologyCortical Cholinergic Function Is More Severely Affected in Parkinsonian Dementia Than in Alzheimer Disease
539 Citations2003Nicolaas I. Bohnen, Daniel Kaufer +7 more
Reduced cortical AChE activity is more characteristic of patients with PDem than of Patients with mild AD, and this work has shown that cholinergic forebrain neuronal losses in parkinsonian dementia are equal to or greater than those in Alzheimer disease.
International Journal of Geriatric PsychiatryMental symptoms in Parkinson's disease are important contributors to caregiver distress
471 Citations1999Dag Aarsland, J. P. Larsen +3 more
To determine the emotional and social distress of caring for a patient with Parkinson's disease and to explore the impact of motor and mental symptoms in subjects with Parkinson’s disease on their caregivers’ situation.
American Journal of PsychiatryA longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration
407 Citations1994Robert G. Stern, Richard C. Mohs +7 more
Cognitive deterioration is slow during the early and very late stages of Alzheimer's disease and more rapid during the middle stages, suggesting that treatment trials and attempts to identify subgroups are affected.
Archives of NeurologyParkinson Disease Neuropathology
399 Citations2002Hülya Apaydın, J. Eric Ahlskog +3 more
Diffuse or transitional Lewy body disease is the primary pathologic substrate for dementia developing later in Parkinson disease and seemed to account for end-stage, levodopa refractory parkinsonism, suggesting common origins or one triggering the other.
NeurologyThe role of radiotracer imaging in Parkinson disease
372 Citations2005Bernard Ravina, David Eidelberg +30 more
No radiotracers fulfill these criteria, and current evidence does not support the use of imaging as a diagnostic tool in clinical practice or as a surrogate endpoint in clinical trials.
Journal of Neurology Neurosurgery & PsychiatryDonepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
342 Citations2002Dag Aarsland
Donepezil improves cognition, and seems to be well tolerated and not to worsen parkinsonism in patients with cognitive impairment.
The Lancet NeurologyChallenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough
338 Citations2004Anthony E. Lang, José Á. Obeso
Restoration of the nigrostriatal dopamine system should not be the ultimate goal of future research, given current medical and surgical experience that emphasises the increasingly critical role of "non-dopaminergic" symptoms to quality of life in late-stage PD.
NeurologyCholinergic dysfunction in diseases with Lewy bodies
328 Citations2000Pietro Tiraboschi, Lawrence A. Hansen +6 more
The LancetHOW COMMON IS DEMENTIA IN PARKINSON'S DISEASE?
323 Citations1984Richard G. Brown, C. D. Marsden
Critical review of the studies on which this conclusion is based indicate that this figure is inflated, and this assertion needs to be put to rigorous examination.
NeurologyThe association of incident dementia with mortality in PD
298 Citations2002Gilberto Levy, M.‐X. Tang +6 more
Movement DisordersRivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial
277 Citations2001Paul Reading, Anna Luce +1 more
In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug, rivastigmine.
The International Journal of Psychiatry in MedicineThe Ten Point Clock Test: A Quick Screen and Grading Method for Cognitive Impairment in Medical and Surgical Patients
264 Citations1994Peter J. Manos, Rae Wu
The ten point clock test is reliable, valid, and useful as a quick screen and grading method for cognitive deficits in medical and surgical patients.
Health Technology AssessmentClinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review
247 Citations2001J Bryant, Andrew Clegg +5 more
Results suggest that donepezil is beneficial using global and cognitive outcome measures, and whether adjustments could be made to existing models to reflect the current situation in England and Wales.
Journal of Geriatric Psychiatry and NeurologyIntellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates
206 Citations1988Jeffrey L. Cummings
Investigation of Parkinson's disease patients reveals that PD patients manifest impairment in memory, visuospatial skills, and set aptitude, and the more severe dementia syndromes have cholinergic alterations or Alzheimer's disease.
International Journal of Geriatric PsychiatryThe cognitive drug research computerized assessment system for demented patients: A validation study
185 Citations1991Paul Simpson, D Surmon +2 more
The utility of the Cognitive Drug Research computerized Assessment System to assess cognitive change should be comparable to that of previous versions used with the young and with non‐demented elderly.
Journal of Neurology Neurosurgery & PsychiatryDegree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease
159 Citations2005Nicolaas I. Bohnen
Donepezil induced inhibition of cortical AChE enzyme activity is modest in patients with mild AD, and the degree of cortical enzyme inhibition correlates with changes in executive and attentional functions.
Movement DisordersProspective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3‐month observations
147 Citations2003Hani T. S. Benamer, Wolfgang H. Oertel +6 more
To record prospectively, from early presentation, the clinical features of parkinsonism and tremor disorders, in relation to evidence of dopaminergic deficit shown with [123I]‐FP‐CIT single photon emission computerised tomography (SPECT), testing for dopamine deficit with SPECT may assist the diagnostic process.
Movement DisordersIs levodopa toxic to human substantia nigra?
109 Citations1997Ali H. Rajput, Mark Fenton +2 more
It is concluded that LD, administered at a dose commonly used for treating Parkinson's disease, was not toxic to SN neurons in these cases.
Archives of Clinical NeuropsychologyAnalyzing the subcortical dementia syndrome of Parkinson's disease using the RBANS
109 Citations2003W. W. Beatty, K. Ryder +4 more
The RBANS is useful for discriminating patterns of cognitive impairment in PD and AD, but only if the diagnosis of dementia is established independent of the RBANS test results.
Movement DisordersChronic L‐DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6‐OHDA or FeCl<sub>3</sub> nigrostriatal lesions
104 Citations2001Krishna P. Datla, Stavia B. Blunt +1 more
Examination of the effects of chronic L‐3,4‐dihydroxyphenylalanine (L‐DOPA) administration on the remaining dopaminergic neurons in rats with 6‐hydroxydopamine (6‐OHDA) or buffered FeCl3 partial lesions to the nigrostriatal tract found no detrimental effects on the number of TH‐positive neurons on the lesioned side of the brain.
Journal of Neurology Neurosurgery & PsychiatryRelationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease.
98 Citations1988S. J. Huber, George W. Paulson +1 more
Severity of rigidity and of bradykinesia did predict severity of intellectual decline, but severity of tremor predicted better intellectual status, suggesting patients with a predominance oftremor may have a more benign clinical course as well as better intellectual function.
Health Technology AssessmentA rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer
94 Citations2001Andrew Clegg, David A. Scott +3 more
The gains in duration of survival with the new drugs are modest - a few months - but worthwhile in a condition for which the untreated survival is only about 5 months, and there are also gains in quality of life compared with BSC, because on balance the side-effects of some forms of chemotherapy have less effect onquality of life than the effects of uncontrolled spread of cancer.
Acta Neurologica ScandinavicaRivastigmine (Exelon) for dementia in patients with Parkinson's disease
91 Citations2003Nir Giladi, H. Shabtai +4 more
The objective is to study the efficacy of cholinesterase inhibitors in the treatment of dementia in patients with Parkinson's disease.
Current Opinion in NeurologyDementia in Parkinson's disease: cause and treatment
87 Citations2004Murat Emre
The prototype of dementia in Parkinson's disease is a dysexecutive syndrome with impaired attention, executive functions and secondarily impaired memory, and the most significant deficit seems to be cholinergic; dementia seems to correlate best with cortical and limbic Lewy bodies.
PubMedThe dementias of Parkinson's disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type.
83 Citations1988Jeffrey L. Cummings
The characteristics of the intellectual changes in PD are those of subcortical dementia and include impaired recall, visuospatial disturbances, executive deficits, bradyphrenia, and depression.
Amino AcidsNeuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease
66 Citations2002Richard M. Kostrzewa, John P. Kostrzewa +1 more
The potential for L-DOPA to 1) autoxidize from a catechol to a quinone, and 2) generate other reactive oxygen species (ROS) is reviewed.
Clinical NeuropharmacologyWorsening of Motor Function and Mood in a Patient With Parkinson's Disease After Pharmacologic Challenge With Oral Rivastigmine
40 Citations2002Irene Hegeman Richard, Anne Wallace Justus +3 more
The case of a patient with PD and cognitive impairment who developed a marked worsening of motor function, mood, and anxiety in the setting of a pharmacologic challenge study using a 3-mg oral dose of the acetylcholinesterase inhibitor, rivastigmine is reported.
PubMedDementia: the University of Oklahoma autopsy experience.
8 Citations2001Leech Rw, Brumback Ra +3 more
The brain from 98 consecutive patients with the clinical diagnosis of dementia were examined at autopsy in a standardized fashion, and almost 60% had another associated pathologic disorder.